Retatrutide + Tirzepatide
This blend contains Retatrutide and Tirzepatide. Retatrutide is characterized as a GIP, GLP-1, and glucagon receptor agonist; Tirzepatide is characterized as a dual GIP and GLP-1 receptor agonist.
Product Procurement
Research-use catalog items with clear ordering, product context, and documentation support.
Retatrutide + Tirzepatide — 60mg
$199.95
Product estimate
- NET VIAL CONTENT
- 60mg
- CATEGORY
- Specialty Compounds
- SKU
- ALS-RETATIRZ-60MG
In stock
Research Use Notice
For laboratory research use only. Not for human or animal use or consumption. Not for diagnostic, therapeutic, or veterinary use. Product documentation and certificates of analysis do not establish safety or suitability for these uses.
Product Intelligence
Retatrutide + Tirzepatide Blend Profile
Retatrutide and Tirzepatide peptide research blend associated with incretin-receptor studies, with 60mg total vial content.
60mg Total Vial Content
Each vial contains 60mg combined total of Retatrutide and Tirzepatide.
GIP / GLP-1 / Glucagon Receptor Context
Literature on the individual components examines receptor activation and the structural basis of multi-receptor peptide interactions. Retatrutide research includes comparative activity at GIP, GLP-1, and glucagon receptors, while Tirzepatide studies examine structural determinants of dual incretin-receptor agonism. These component studies provide a framework for receptor-focused research. (Coskun et al., 2022; PMID 35985340; Sun et al., 2022; PMID 35333651.)
- Product TypePeptide blend
- ComponentsRetatrutide; Tirzepatide
- Total Vial Content60mg
- IdentifierRetatrutide: PubChem SID 528343961; Tirzepatide: PubChem CID 166567236
Documentation
Verification & Documentation
Documentation is handled by product and lot. Use Standards to search for a matching record; if none appears, contact support with the product name, SKU, and lot number.